MedPath

Iodide I-123

Generic Name
Iodide I-123
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
I
CAS Number
69239-56-1
Unique Ingredient Identifier
98QPV8670C
Background

Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect the decay by electron capture to tellurium-123.

Iodine is commonly used in thyroid function diagnostic tests as this gland normally absorbs iodine through the diet for formation of the thyroid hormones triiodothyronine (T3) and its prohormone, thyroxine (T4). Radioactive I-123 in particular is effective for this use as its half-life of approximately 13.13 h (hours) is ideal for the 24-h (hour) iodine uptake test and it has a reduced radiation burden as compared to I-131.

Indication

Administration of Sodium Iodide I 123 Capsules is indicated as a diagnostic procedure to be used in evaluating thyroid function and/or morphology.

Associated Conditions
Thyroid cancer metastases
Associated Therapies
-
uclh.nhs.uk
·

First patient takes part in new Phase 1 clinical trial for patients with recurrent glioblastoma

A new clinical trial for recurrent glioblastoma brain cancer, CITADEL-123, has opened at UCLH. Paul, a 62-year-old engineer, is the first patient to participate, showing a 50% reduction in tumour size after treatment. The trial involves an Ommaya reservoir for drug delivery and is sponsored by Ariceum Therapeutics.
frontiersin.org
·

Theranostics as a Driving Force in Nuclear Medicine

Theranostics, precision medicine using PET imaging to identify targets for therapy, has evolved rapidly in nuclear medicine. Examples include 18F-FGFR1 for FGFR1-expressing tumors, 89Zr-girentuximab for hypoxia imaging, and PSMA-targeted radiotracers for ccRCC. Clinical applications like PSMA-targeted theranostics in non-prostate cancers and individualized dosimetry with lutetium-177-labeled agents are discussed. The potential of digital twins for personalized dosing is also highlighted, emphasizing the need for continued research and technological advancements.
© Copyright 2025. All Rights Reserved by MedPath